Drug Trial Radar · NCT04652102
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39,680
Actual
Start
Dec 11, 2020
Primary completion
Jun 10, 2022
Study completion Jun 10, 2022
Sponsor
- Lead sponsor
- CureVacIndustry
- Sponsor type
- Industry
- First posted
- Dec 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.
Conditions
- Covid19
- SARS-CoV-2
Interventions
CVnCoVBiological
Intramuscular (IM) injection.
PlaceboBiological
Intramuscular (IM) injection.
Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination programBiological
Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any SeverityTime frame: Day 44 to Day 393
- Number of Participants Who Experienced One or More Medically-attended Adverse Events (AE)Time frame: Day 1 to Day 211
- Number of Participants Who Experienced One or More Serious AE (SAE)Time frame: Day 1 to Day 393
- Intensity of SAEs as Per Investigator AssessmentTime frame: Day 1 to Day 393
- Number of Participants Who Experienced One or More Adverse Event of Special Interest (AESI)Time frame: Day 1 to Day 393
- Number of Participants Who Experienced a Fatal SAETime frame: Day 1 to Day 393
- Phase 2b Participants Only: Number of Participants Who Experienced One or More Solicited AETime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
- Phase 2b Participants Only: Intensity of Solicited AEs as Per Investigator AssessmentTime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
- Phase 2b Participants Only: Duration of Solicited AEsTime frame: Up to 7 days after vaccination (Days 1 to 7 and Days 29 to 36)
- Phase 2b Participants Only: Number of Participants Who Experienced One or More Unsolicited AETime frame: Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)
- Phase 2b Participants Only: Intensity of Unsolicited AEs as Per Investigator AssessmentTime frame: Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)
- Number of Participants Who Experienced One or More AEs Leading to Vaccine Withdrawal or Trial DiscontinuationTime frame: Day 1 to Day 393
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
Instituto de Investigaciones Clinicas Quilmes
Buenos Aires, Argentina
Hospital Interzonal General Agudos Prof. Dr. Ramon Carrillo
Buenos Aires, Argentina
Hospital Interzonal General de Agudos Vicente Lopez y Planes
Buenos Aires, Argentina
Hospital Zonal General de Agudos Descentralizado Evita Pueblo de Berazategui
Buenos Aires, Argentina
Fundación Cenit Para La Investigación En Neurociencias
Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Argentina
Sanatorio Parque
Rosario, Argentina
Corporación Médica Sanatorio
San Martin, Argentina
Instituto De Investigaciones Clinica Zarate
Zárate, Argentina
Cohezio - Bruxelles
Brussels, Belgium
Mensura
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Clínica de la Costa
Barranquilla, Colombia
CAIMED - Bogota Clinical Research Center
Bogotá, Colombia
Centro de Estudios en Infectología Pediátrica (CEIP)
Cali, Colombia
Fundacion Dominicana de Perinatologia Pro Bebe
Santo Domingo, Dominican Republic
Instituto Dermatológico Dominicano y Cirugía de Piel Dr. Huberto Bogaert Díaz
Santo Domingo, Dominican Republic
Clínica Cruz Jiminian
Santo Domingo, Dominican Republic
Hospital General Regional Marcelino Vélez Santana
Santo Domingo, Dominican Republic
Uniklinik Köln
Cologne, Germany
Ludwig-Maximilians-Universität München
München, Germany
Universitätsklinikum Tübingen - Institut für Tropenmedizin, Reisemedizin und Humanparasitologie
Tübingen, Germany
Panamerican Clinical research Mexico (Guadalajara)
Guadalajara, Mexico
Panamerican Clinical Research Mexico S.A. DE C.V.
Juriquilla, Mexico
Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran
Mexico City, Mexico
CAIMED - México
Mexico City, Mexico
Unidad de Medicina Especializada SMA
San Juan del Río, Mexico
Centro Medico Zambrano Hellion TecSalud
San Pedro Garza García, Mexico
Noordwest Ziekenhuisgroep
Alkmaar, Netherlands
Amsterdam Universitair Medische Centra - Academisch Medisch Centrum
Amsterdam, Netherlands
The Julius Center - Utrecht Science Park - Stratenum
Utrecht, Netherlands
Centro De Vacunacion Internacional - CEVAXIN Chorreras
Panama City, Panama
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología
Panama City, Panama
Centro De Vacunacion Internacional - CEVAXIN 24 Diciembre
Panama City, Panama
Centro de Vacunacion Internacional - CEVAXIN Avenida Mexico
Panama City, Panama
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales
Callao, Peru
Hospital de Chancay y Servicios básicos de Salud
Chancay, Peru
Clinica Medica San Martin
Ica, Peru
Instituto de Investigación Nutricional - Las Gardenias
Lima, Peru
Instituto de Investigación Nutricional - San Carlos
Lima, Peru
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.